Izgu lab is awarded the National Institutes of Health’s Research Evaluation and Commercialization Hub (REACH) grant through the HealthAdvance platform of Rutgers Optimizes Innovation Program. Details will be available soon.

Bryan receives Rieman Award, which recognizes graduate students for excellence in undergraduate teaching. Congrats Bryan! 

John and Kern publish a versatile chemical strategy that enables site-specific functionalization of materials in ACS Appl. Mater. Interfaces. This work, titled "Catecholamine-Copper Redox as a Basis for Site-Specific Single-Step Functionalization of Material Surfaces", provides a robust platform for the prevention of bacterial adhesion and biofilm formation, cell differentiation, and tissue engineering.

Bryan's research proposal on the investigation of lipid membrane reactivity in diseased cells receives funding from the Rutgers Center for Lipid Research. Congrats Bryan! 

A highly configurable RNA-based imaging technology that Tushar is developing leads to a provisional patent. Congrats Tushar, and thanks to the Rutgers ORED and NIH for supporting this technology.

E.C. Izgu receives the NIH, National Institute of Biomedical Imaging and Bioengineering (NIBIB) Trailblazer Award. The NIH / NIBIB Trailblazer Award is a great opportunity for early-stage investigators to pursue high-impact research programs of high interest to the NIH and NIBIB at the interface of the life and physical sciences. We are thrilled to have this recognition from the NIH for our ongoing efforts in building bioorthogonal platforms to investigate aberrant metabolic pathways and how pathogenesis originates in the cell. For details and highlights, check out the Departmental News and Rutgers Newsletter, The Current.

The Yildirim et al. (Bob Kingston Lab, HMS) collaborative work titled "S-Phase enriched non-coding RNAs regulate gene expression and cell cycle progression" has been published in Cell Reports.

Izgu Lab and Biological Mimetics, Inc. (BMI) join forces to combat viral pathogens that are extremely potent and easily transmissible. BMI is a leading biopharma company that specializes on vaccine development against some of the most severe viruses that affect humans.  

The Materials Research Team including the Izgu Lab receives funding from the Chancellor's Office of Rutgers to engineer co-stimulatory protocells as therapeutic agents against cancer.

The next-generation material surface functionalization technology that Zhaojun (John) Jia is developing leads to a provisional patent. 

Congrats John, and thanks to the Rutgers ORED for supporting our technology. Update: PCT application filed in Dec 2020.

A team of Rutgers faculty including E.C. Izgu receives funding from the Chancellor's Office of Rutgers for the in vitro design and in vivo implementation of synthetic cells.

The lab receives the Charles and Johanna Busch Biomedical Grant Award. Thanks to the Rutgers, Office of Research and Economic Development (ORED) for supporting our research.

E.C. Izgu receives the 2019 American Cancer Society Institutional Research Grant Early Investigator Award. This award is also complemented with additional funding from the Cancer Institute of New Jersey. Thanks to ACS and CINJ for supporting our lab.